Attached files

file filename
EX-99.1 - EXHIBIT 99.1 JPM TRANSCRIPT - HALOZYME THERAPEUTICS INChalotranscript20180109.htm


Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
January 9, 2018
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
of incorporation)
File Number)
(IRS Employer
Identification No.)
11388 Sorrento Valley Road, San Diego, California
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code:
(858) 794-8889
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.

On January 9, 2018, Halozyme Therapeutics, Inc., a Delaware corporation (“Halozyme”), presented at the annual JP Morgan Healthcare Conference, providing a corporate update on certain strategic programs and financial guidance for 2018. The presentation contained information related to various aspects of Halozyme’s expected 2017 results of operation and financial condition. A copy of the transcript of this presentation is attached hereto as Exhibit 99.1.

Exhibit 99.1 is furnished under Item 2.02 of this report and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 9.01. Financial Statements and Exhibits.


Exhibit No.        Description

99.1            Transcript of Halozyme Therapeutics, Inc. corporate update presentation,
dated January 9, 2018



Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Halozyme Therapeutics, Inc.
January 12, 2018
/s/ Harry J. Leonhardt, Esq.
Harry J. Leonhardt, Esq. 

Senior Vice President, General Counsel,
Chief Compliance Officer and Corporate Secretary

Exhibit Index